STOCK TITAN

Solid Biosciences to Participate at Cantor’s Virtual Muscular Dystrophy Symposium

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Solid Biosciences Inc. to present at Cantor's Virtual Muscular Dystrophy Symposium. Bo Cumbo, CEO, and Gabriel Brooks, CMO, will discuss precision genetic medicines for neuromuscular and cardiac diseases on April 2, 2024.
Positive
  • None.
Negative
  • None.

CHARLESTOWN, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and Chief Executive Officer, and Gabriel Brooks, M.D., Chief Medical Officer, will present at Cantor’s Virtual Muscular Dystrophy Symposium on Tuesday, April 2, 2024, at 8:15 am ET.

A live webcast of the presentation will be available on the Events page of the Investors section of the Company website or by clicking here. A webcast replay will be archived for 30 days on the Events page.

About Solid Biosciences
Solid Biosciences is a life sciences company focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy (Duchenne), SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT), AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy, and additional assets for the treatment of fatal cardiac diseases. Solid is advancing its diverse pipeline across rare neuromuscular and cardiac diseases, bringing together experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted, Solid’s mandate is to improve the daily lives of patients living with these devastating diseases. For more information, please visit www.solidbio.com.

Solid Biosciences Contact:
Leah Monteiro
VP, Investor Relations & Communications
617-766-3430
lmonteiro@solidbio.com


Solid Biosciences Inc. will present at Cantor's Virtual Muscular Dystrophy Symposium on Tuesday, April 2, 2024, at 8:15 am ET.

Bo Cumbo, President and CEO, and Gabriel Brooks, Chief Medical Officer, will be presenting at the symposium.

The live webcast of the presentation will be available on the Events page of the Investors section of the Company website or by clicking on the provided link.

The webcast replay will be archived for 30 days on the Events page of the Company website.
Solid Biosciences Inc

NASDAQ:SLDB

SLDB Rankings

SLDB Latest News

SLDB Stock Data

Biological Product (except Diagnostic) Manufacturing
Manufacturing
Health Technology, Biotechnology, Manufacturing, Biological Product (except Diagnostic) Manufacturing

About SLDB

solid biosciences (solid) is a cambridge, ma based biotech company singularly focused on developing treatments and cures for duchenne muscular dystrophy (dmd). solid combines sharp commercial focus with world-class science to advance promising therapies and is positioned to catalyze therapeutic development across all aspects of the disease. condition-focused, our mandate is comprehensive; improving daily life for patients and attacking the roots of dmd.